There is a challenge related to prostate and many other cancers that cancer cells form resistance to treatments as the disease progresses. However, these resistance mechanisms are not yet fully understood. A new study by the University of Eastern Finland found that inflammation-promoting immune cells, M1 macrophages, can transform cancer cells into stem-like cells and thus immune to treatment. The results were published in OncoImmunology journal.

The study examined the impact of factors promoting inflammation in a tumour microenvironment on the progression of prostate cancer. Researchers focused particularly on the role of M1 and M2 macrophages in the tumour microenvironment. Macrophages are immune cells whose large number in the tumour area is often a sign of poor prognosis in relation to prostate cancer. The study found that pro-inflammatory macrophages (M1) increase the stem cell traits of cancer cells and weaken the androgen response.

“We found that pro-inflammatory M1 macrophages secreted factors that increased the expression of stem cell markers such as NANOG, KLF4, SOX2 and CD44 in prostate cancer cells. Based on our research, it seems that inflammatory tumour microenvironment promotes the transformation of prostate cancer cells into a stem cell-like state where they are resistant to traditional therapies,” says Doctoral Researcher Kirsi Kainulainen.

The results help us understand how immune response affects the progression of prostate cancer and resistance to treatments. Observations on the effects of immune cells on the transformation capacity of cancer cells may open up new treatment opportunities for prostate cancer.

The study was carried out by Senior University Lecturer Sanna Pasonen-Seppänen and Research Director Kirsi Ketola at the University of Eastern Finland’s Institute of Biomedicine. The study has been supported by the Academy of Finland, the Sigrid Juselius Foundation, the Cancer Foundation Finland, the North Savo Cancer Association, the Finnish Cultural Foundation, the Northern Savo Cultural Foundation, the Paavo Koistinen Foundation and the Kuopio University Foundation.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What has leaves, a trunk, and branches, and grows in forests?

Explore More

Study helps predict how long it will take for testosterone to return to normal after prostate cancer treatment

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer,

Most top-selling, over-the-counter sexual treatments unproven, some could be harmful, review shows

From horny goat weed to ginseng and maca, over-the-counter dietary supplements sold to improve male sexual health contain a wide variety of “natural” ingredients. Researchers from Wake Forest Baptist Medical

Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results